Methicillin-resistant Staphylococcus aureus or (MRSA) is skin infection which occurs mostly in healthcare facilities and hospitals. The infection is treated with commonly used antibiotics and it is highly contagious. The infection is difficult to treat as it is resistant to the commonly-used antibiotics including methicillin. The aging people are highly vulnerable to MRSA infections, particularly in the hospital setting as the weak immune system makes such people easily prone to the diseases and infections. Early detection of these infections and growing awareness of the treatment drugs are expected to positively aid in growth of the market in the coming years.
The surge in number of infections and the infectious diseases is generating unmet needs in market. This has driven the non-governmental and government-based institutes to take initiatives to develop antibiotics by providing necessary funding to companies and research institutes. Several nations across globe are actively giving funds to develop the antibacterial drugs and also fight drug resistance and its surveillance. Such aid encourages companies and research institutes to invest more in the antibiotic research, thus resulting in growth of the market.
Segment Overview
Tetracyclines prevent bacterial protein synthesis via reversibly binding to bacterial 30S ribosomes. The drugs act against the Gram-positive and the Gram-negative bacteria; though, most of drugs develop resistance, thus indicate limited activity. Few commonly recommend drugs that treat infection include doxycycline, tetracycline, and minocycline.
Regional Overview
The North America dominated MRSA drugs market in 2019 and accounted for over 71% of the market share. Much of region’s growth can be accredited to availability of better the healthcare infrastructure coupled with presence of favourable reimbursement policies and co-pay support programs for patients. With adoption of favourable regulatory initiatives for approval of antibiotics, numerous drug developers in region are concentrating on developing the new treatment options.
Competitor overview
Currently, the market is rising at slow pace because of increased use of the generics. The inaccessibility of effective treatment choices and improved development of the drug resistance is leading to the unmet needs in market. This has pushed numerous vendors to engage vigorously in R&D activities. Moreover, the market is anticipated to witness entry of several new companies during forecast period. The vendors are concentrating on both the manufacturers as well as the market their products with the high safety and efficiency profile, to gain competitive edge in market.
Basilea Pharmaceutica, one of leading drug manufacturer, entered into license agreement for anti-MRSA antibiotic Zevtera with the Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. Such key initiatives being adopted by manufacturers is likely to propel growth of MRSA drugs over the forecast period.
Key Players
- Allergan
- Merck
- Pfizer
- Theravance Biopharma
- Basilea Pharmaceutica,
- The Medicines Company,
- Theravance Biopharma,
Market Segmentation
By Drug Class
- Tetracycline
- Folate antagonist
- Lipopeptides
- Cephalosporin
- Oxazolidinone
- Lipoglycopeptide
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
Request for TOC
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
